Inhibrx Biosciences IncNASDAQ:INBX
- LAST PRICE13.6100
- TODAY'S CHANGE (%)0.7200 (5.5857%)
- Bid / Lots13.2000/ 1
- Ask / Lots15.5500/ 1
- Open / Previous Close12.9200 / 12.8900
- Day Range
- 52 Week Range
- Volume136,977
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INBX |
|---|---|---|
| 09:32 ET | 4159 | 14.09 |
| 09:36 ET | 600 | 14.32 |
| 09:38 ET | 300 | 13.68 |
| 09:39 ET | 300 | 13.12 |
| 09:41 ET | 400 | 13.42 |
| 09:43 ET | 797 | 13.07 |
| 09:48 ET | 2468 | 12.95 |
| 09:50 ET | 200 | 13.17 |
| 09:52 ET | 300 | 13.18 |
| 09:54 ET | 100 | 12.97 |
| 09:56 ET | 500 | 13.2 |
| 09:57 ET | 100 | 13.1 |
| 09:59 ET | 1900 | 13.09 |
| 10:03 ET | 156 | 13.2 |
| 10:06 ET | 400 | 13.2 |
| 10:10 ET | 200 | 13.2 |
| 10:12 ET | 200 | 13.115 |
| 10:14 ET | 13600 | 13.115 |
| 10:15 ET | 8375 | 13.18 |
| 10:19 ET | 200 | 13.2 |
| 10:24 ET | 400 | 13.2 |
| 10:28 ET | 300 | 13.33 |
| 10:30 ET | 400 | 13.315 |
| 10:32 ET | 249 | 13.315 |
| 10:33 ET | 14145 | 13.32 |
| 10:37 ET | 900 | 13.24 |
| 10:39 ET | 500 | 13.25 |
| 10:42 ET | 500 | 13.25 |
| 10:44 ET | 600 | 13.4 |
| 10:46 ET | 200 | 13.28 |
| 10:48 ET | 300 | 13.42 |
| 10:50 ET | 100 | 13.325 |
| 10:51 ET | 129 | 13.33 |
| 10:53 ET | 618 | 13.53 |
| 10:55 ET | 100 | 13.49 |
| 10:57 ET | 200 | 13.6 |
| 11:00 ET | 100 | 13.6 |
| 11:02 ET | 200 | 13.76 |
| 11:04 ET | 500 | 13.77 |
| 11:08 ET | 100 | 13.685 |
| 11:15 ET | 290 | 13.7543 |
| 11:22 ET | 100 | 13.71 |
| 11:31 ET | 100 | 13.705 |
| 11:33 ET | 673 | 13.705 |
| 11:45 ET | 1013 | 13.6 |
| 11:47 ET | 700 | 13.59 |
| 12:00 ET | 325 | 13.5 |
| 12:30 ET | 337 | 13.59 |
| 12:52 ET | 520 | 13.685 |
| 12:57 ET | 350 | 13.67 |
| 12:59 ET | 100 | 13.715 |
| 01:03 ET | 650 | 13.63 |
| 01:28 ET | 200 | 13.615 |
| 01:30 ET | 200 | 13.615 |
| 01:32 ET | 100 | 13.615 |
| 01:33 ET | 100 | 13.615 |
| 01:35 ET | 100 | 13.62 |
| 01:42 ET | 100 | 13.67 |
| 01:50 ET | 100 | 13.63 |
| 01:55 ET | 217 | 13.63 |
| 02:04 ET | 300 | 13.58 |
| 02:15 ET | 700 | 13.705 |
| 02:18 ET | 684 | 13.725 |
| 02:20 ET | 264 | 13.7265 |
| 02:22 ET | 425 | 13.68 |
| 02:36 ET | 1378 | 13.59 |
| 02:38 ET | 952 | 13.56 |
| 02:44 ET | 500 | 13.51 |
| 02:47 ET | 100 | 13.585 |
| 03:03 ET | 100 | 13.59 |
| 03:07 ET | 200 | 13.5 |
| 03:09 ET | 200 | 13.46 |
| 03:18 ET | 100 | 13.4 |
| 03:20 ET | 100 | 13.46 |
| 03:23 ET | 100 | 13.39 |
| 03:27 ET | 742 | 13.4125 |
| 03:32 ET | 100 | 13.35 |
| 03:34 ET | 100 | 13.4 |
| 03:36 ET | 100 | 13.37 |
| 03:38 ET | 100 | 13.37 |
| 03:41 ET | 200 | 13.375 |
| 03:43 ET | 200 | 13.36 |
| 03:45 ET | 1516 | 13.415 |
| 03:48 ET | 100 | 13.435 |
| 03:50 ET | 100 | 13.42 |
| 03:52 ET | 200 | 13.44 |
| 03:54 ET | 200 | 13.425 |
| 03:56 ET | 1127 | 13.465 |
| 03:57 ET | 3702 | 13.55 |
| 03:59 ET | 20011 | 13.61 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibrx Biosciences Inc | 186.6M | -2.5x | --- |
Century Therapeutics Inc | 189.3M | -1.0x | --- |
Abeona Therapeutics Inc | 186.0M | -1.5x | --- |
Shattuck Labs Inc | 175.0M | -1.8x | --- |
Rani Therapeutics Holdings Inc | 188.6M | -2.8x | --- |
Aldeyra Therapeutics Inc | 189.5M | -6.5x | --- |
Company Information
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Contact Information
- Headquarters
- 11025 N. Torrey Pines Road, Suite 140LA JOLLA, CA, United States 92037
- Phone
- 858-795-4220
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $186.6M |
|---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-5.35 |
Book Value | $0.92 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 104.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13,980.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
